British medics have made an important statement about the treatment of covid with aspirin, which is included in medical protocols in many countries.
According to a large-scale study, this drug does not improve the survival of hospitalized with COVID-19 and there is no need to prescribe it if such a patient has not taken the drug for other reasons before coronavirus.
The research paper revealed that “there was no evidence that aspirin treatment reduced mortality” and “no significant difference” in the number of people that died, with 17% of people in both groups dying in hospital after 28 days.
- Does This Mean We Stopped Being Animal and Started Being Human Due to ‘Copy Paste’ Errors?
- The One Lifestyle Choice That Could Reduce Your Heart Disease Risk By More Than 22%
- Aging: This Is What Happens Inside Your Body Right After Exercise
- Immune-Boosting Drink that Mimics Fasting to Reduce Fat – Scientists ‘Were Surprised’ By New Findings
- Gun Violence in America: What They Don’t Talk About at the Debate
It is reported that from November 2020 to March 2021, about 15,000 patients took part in the British study: 7351 received aspirin (150 mg once a day), and 7,541 people were treated without this drug.
Now doctors report that they have not been able to prove that aspirin somehow reduces the risks and protects the infected from death or the ventilator. Experts did not see a significant difference in 28-day mortality (17% in the aspirin group and 17% in the placebo group).
However, in those patients who took aspirin in the hospital, the length of hospital stay was slightly shorter (by 1%).
- Does This Mean We Stopped Being Animal and Started Being Human Due to ‘Copy Paste’ Errors?
- The One Lifestyle Choice That Could Reduce Your Heart Disease Risk By More Than 22%
- Aging: This Is What Happens Inside Your Body Right After Exercise
- Immune-Boosting Drink that Mimics Fasting to Reduce Fat – Scientists ‘Were Surprised’ By New Findings
- Gun Violence in America: What They Don’t Talk About at the Debate
The results of the latest research paper, submitted to a leading peer-reviewed medical journal, to be published shortly on pre-print site medRxiv as cited by CNBC.
Image Credit: Getty